Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens

Genetics and Molecular Research

Volumn 10, Issue 4, 2011, Pages

  Huang, M Y ^a,b   Chen, M J ^c   Tsai, H L ^a,d   Kuo, C H ^a,b   Ma, C J ^a   Hou, M F ^a,b   Chuang, S C ^a,b   Lin, S R ^e   Wang, J Y ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d FOOYIN UNIVERSITY   (Taiwan)

^e FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

2nd or 3rd line setting; Cetuximab; KRAS; Metastatic colorectal cancer; Wild type

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PARONYCHIA; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; WILD TYPE; FOLLOW UP; GENETIC ANALYSIS; METASTATIC COLORECTAL CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG TOXICITY; GENETICS; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85046981718     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2011.October.3.4     Document Type: Article

References (32)

1. Arnold D, Hohler T, Dittrich C, Lordick F, et al. (2008). Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann. Oncol. 19: 1442-1449.
2. Bleiberg H (1996). Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol. 23: 42-50.
3. Cunningham D, Humblet Y, Siena S, Khayat D, et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351: 337-345.
4. Department of Health (2007). Executive Yuan, Taiwan, ROC, Statistics on Leading Causes of Cancer Death.
5. Fakih M (2008). The role of targeted therapy in the treatment of advanced colorectal cancer. Curr. Treat. Options Oncol. 9: 357-374.
6. Fang JY and Richardson BC (2005). The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6: 322-327.
7. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, et al. (2006). Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17: 450-456.
8. Giacchetti S, Perpoint B, Zidani R, Le BN, et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18: 136-147.
9. Giovanella BC, Stehlin JS, Wall ME, Wani MC, et al. (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048.
10. Hemming AW, Davis NL, Kluftinger A, Robinson B, et al. (1992). Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol. 51: 147-152.
11. Kallen KJ, Hofmann MA, Timm A, Godderz W, et al. (2000). Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Z. Gastroenterol. 38: 153-157.
12. Lenz HJ, Van CE, Khambata-Ford S, Mayer RJ, et al. (2006). Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24: 4914-4921.
13. Lievre A, Bachet JB, Boige V, Cayre A, et al. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26: 374-379.
14. Liu LF, Desai SD, Li TK, Mao Y, et al. (2000). Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 922: 1-10.
15. Loe DW, Deeley RG and Cole SP (1996). Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 32A: 945-957.
16. Maindrault-Goebel F, de GA, Louvet C, Andre T, et al. (2001). High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 37: 1000-1005.
17. Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, et al. (2008). Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br. J. Cancer 99: 455-458.
18. Midgley RS, Yanagisawa Y and Kerr DJ (2009). Evolution of nonsurgical therapy for colorectal cancer. Nat. Clin. Pract. Gastroenterol. Hepatol. 6: 108-120.
19. Min BS, Kim NK, Ahn JB, Roh JK et al. (2007). Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 30: 637-643.
20. Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
21. Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, et al. (2007). Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol. 46: 697-701.
22. Recchia F, Candeloro G, Necozione S, Bratta M, et al. (2008). Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 31: 323-328.
23. Reidy D and Saltz L (2007). Targeted strategies in the treatment of metastatic colon cancer. J. Natl. Compr. Canc. Netw. 5: 983-990.
24. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, et al. (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22: 1201-1208.
25. Sambrook J, Jritsch E and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, New York.
26. Tabernero J, Van CE, Diaz-Rubio E, Cervantes A, et al. (2007). Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25: 5225-5232.
27. Teufel A, Steinmann S, Siebler J, Zanke C, et al. (2004). Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 4: 38.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216.
29. van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, et al. (1998). Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br. J. Cancer 77: 2171-2176.
30. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360: 1408-1417.
31. Wang JY, Hsieh JS, Chen FM, Yeh CS, et al. (2003). High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int. J. Cancer 107: 387-393.
32. Yen LC, Uen YH, Wu DC, Lu CY, et al. (2010). Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann. Surg. 251: 254-260.